You just read:

Pharmazz, Inc. initiates human phase II studies of PMZ-2010 for the treatment of hemorrhagic shock and presents data at the Society of Critical Care Medicine Annual Meeting

News provided by

Pharmazz, Inc.

Feb 03, 2017, 07:00 ET